Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

ACTIVE NOT RECRUITING

Identifier: CI-TRIAL-00111773
Entity page: /trial/NCT04380636 ↗
Edges: 10

Neighbours: 2 cancers8 drugs
Drawn: 10 of 10 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) condition of …CONDITION_OFderived2 of 2
← condition of	Lung Neoplasm registry condition “Lung Neoplasms” mapped ONTOLOGY_EXACT	—	—	Lung Neoplasm	1	Observed	clinicaltrials	graph →
← condition of	Lung Non-Small Cell Carcinoma registry condition “Carcinoma, Non-Small-Cell Lung” mapped ALIAS	—

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) intervention of …INTERVENTION_OFderived8 of 8
← intervention of	Carboplatinsmall molecule registry intervention “Carboplatin” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Cisplatinsmall molecule registry intervention “Cisplatin” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Durvalumabmonoclonal antibody registry intervention “Durvalumab” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Etoposidesmall molecule registry intervention “Etoposide” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Olaparibsmall molecule registry intervention “Olaparib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Paclitaxelsmall molecule registry intervention “Paclitaxel” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Pembrolizumabmonoclonal antibody registry intervention “Pembrolizumab” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Pemetrexedsmall molecule registry intervention “Pemetrexed” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) intervention of …INTERVENTION_OFderived8 of 8

← intervention of

Carboplatinsmall molecule

registry intervention “Carboplatin” (DRUG) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →

← intervention of

Cisplatinsmall molecule

registry intervention “Cisplatin” (DRUG) mapped ALIAS

—